[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Muenster\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":425},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,69,102,128,154,176,202,224,252,275,309,335,355,373,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638966","biomechanical-effects-of-emst-on-swallowing-function-in-parkinsons-disease-100638966",false,"NCT07606547","Biomechanical Effects of EMST® on Swallowing Function in Parkinson's Disease","Biomechanical Effects of Expiratory Muscle Strength Training (EMST®) on Swallowing Function in Parkinson's Disease - a Prospective High-resolution Manometry Study","Inclusion Criteria:\n\n* diagnosis of Parkinson's disease,\n* PD-related dysphagia as objectively diagnosed with FEES\n\nExclusion Criteria:\n\n* severe dementia, not able to give consent\n* dysphagia related to other diagnoses","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this non-randomized intervention study is to investigate the detailed effects of a structured four-week EMST® training program on the biomechanics of swallowing function in dysphagic Parkinson's patients. A combination of fiberoptic endoscopic evaluation of swallowing (FEES) and pharyngeal high-resolution manometry (HRM) will be employed to comprehensively evaluate the neuromuscular changes in swallowing.",[26,27],"Parkinson's Disease (PD)","Dysphagia",[27,29,30,31],"Expiratory muscle strength training","Parkinson's Disease","High-resolution pharyngeal manometry","RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":20},"2026-06",{"date":40,"type":20},"2028-05",{"name":42,"class":43},"University Hospital Muenster","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100365840","phase-3-international-cooperative-treatment-protocol-for-children-and-adolescents-with-lymphoblastic-lymphoma-100365840","NCT04043494","International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","LBL 2018","Inclusion criteria:\n\n* newly diagnosed lymphoblastic lymphoma\n* age \\\u003C18 years\n* patient enrolled in a participating center\n* written informed consent of patient (\\>14 years of age or according to local law and regulation) and parents to trial participation and transfer and processing of data\n* willingness of patients and the investigator\u002Fpathologist to provide adequate slides\u002Fblocks for reference (molecular) pathology and international pathology panel and\u002For fresh or fresh frozen samples for genetic risk group stratification if these samples are available after standard diagnostic procedures.\n\nExclusion criteria:\n\n* lymphoblastic lymphoma as secondary malignancy\n* non-lymphoma related relevant medical, psychiatric or social conditions incompatible with trial treatment, including among others\n\n  * prior organ transplant\n  * severe immunodeficiency\n  * demyelinating Charcot-Marie Tooth syndrome\n  * serious acute or chronic infections, such as HIV, VZV and tuberculosis\n  * urinary tract infection, cystitis, urinary outflow obstruction, severe renal impairment (creatinine clearance less than 20 ml\u002Fmin)\n  * severe hepatic impairment (bilirubin \\>3 times ULN, transaminases \\>10 times ULN)\n  * myocardial insufficiency, severe arrhythmias\n  * ulcers of the oral cavity and known active gastrointestinal ulcer disease\n  * known hypersensitivity to any IMP and to any excipient (listed in section 6.1 of the respective SmPC)\n* steroid pre-treatment with ≥ 1 mg\u002Fkg\u002Fd for more than two weeks during the last month before diagnosis\n* vaccination with live vaccines within 2 weeks before start of protocol treatment\n* treatment started according to another protocol or pre-treatment with cytostatic drugs\n* participation in another clinical trial that interferes with the protocol, except NHL-BFM Registry 2012 and trials with different endpoints, involving aspects of supportive treatment, which can run parallel to LBL 2018 without influencing the outcome of this trial (e.g. trials on antiemetics, antibiotics, strategies for psychosocial support)\n* evidence of pregnancy or lactation period\n* sexually active adolescents not willing to use highly effective contraceptive method (pearl index \\\u003C 1) until 12 months after end of cytostatic therapy",{"count":54,"type":20},683,[56],"PHASE3","Primary objectives:\n\n* Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm)\n* Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)",[59],"Lymphoblastic Lymphoma, Childhood","2026-04-29",{"date":62,"type":36},"2026-05-06",{"date":64,"type":36},"2019-08-23",{"date":66,"type":20},"2030-04-22",{"name":42,"class":43},228,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":44},"100624812","micro-surg-subgingival-microbiome-in-peri-implantitis-regenerative-and-resective-periodontal-surgery-100624812","NCT07414498","MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery","MICRO-SURG: Investigation of Subgingival Microbiome Changes Following Surgical Peri-Implantitis Therapy, Regenerative Periodontal Surgery, and Resective Periodontal Surgery Using Next-Generation Sequencing","MICROSURG","Inclusion Criteria:\n\n* Age 18 years or older\n* Confirmed diagnosis of Peri-implantitis (for the peri-implantitis surgery arm), or Stage III\u002FIV periodontitis (for the periodontal surgery arms)\n* Indication for surgical therapy corresponding to the assigned study arm\n* Ability to understand the study procedures and provide written informed consent\n* Adequate oral hygiene (API\u002FSBI according to the clinician's judgment)\n* Willingness and ability to attend all follow-up visits\n* Willingness to provide salivary and subgingival plaque samples for microbiome analyses (NGS, SMDI)\n\nExclusion Criteria:\n\n* Systemic conditions contraindicating oral surgical procedures\n* Severe systemic diseases (e.g., uncontrolled diabetes mellitus, immunosuppressive disorders)\n* Use of systemic antibiotics within the previous 3 months\n* Active COVID-19 infection at the time of surgery\n* Pregnancy or breastfeeding\n* Drug or alcohol abuse\n* Smoking more than 10 cigarettes per day\n* Known allergies to materials used in the assigned intervention (e.g., local anesthetics, sutures, membranes, bone grafting materials)\n* Participation in another clinical study within the previous 30 days\n* Acute oral infections that contraindicate participation\n* Inability or unwillingness to comply with all follow-up appointments Lack of capacity to provide informed consent","80 Years",{"count":79,"type":20},84,[23],"This clinical study investigates how the subgingival microbiome changes after three different periodontal and peri-implant surgical procedures: (1) resective periodontal surgery, (2) regenerative periodontal surgery, and (3) peri-implantitis surgery. The aim is to characterize microbial shifts associated with these commonly used surgical treatments and to determine whether the type of surgery influences the recovery or disruption of the subgingival ecosystem. Adult patients with periodontitis or peri-implantitis will receive the procedure indicated for their condition. Subgingival plaque samples will be collected at baseline and at defined postoperative follow-up intervals. Microbiome analysis will be performed using next-generation sequencing (NGS), and microbial changes will be evaluated with the Subgingival Microbial Dysbiosis Index (SMDI). Insights from this study may help improve prevention, diagnostics, and treatment strategies for periodontal and peri-implant diseases.",[83,84],"Periodontitis","Periimplantitis",[86,87,88,89,90,91,92,93,94],"Subgingival Microbiome","Periodontal Surgery","Regenerative Surgery","Resective Surgery","Peri-Implantitis Surgery","Next-Generation Sequencing","16S rRNA Sequencing","Microbiome Analysis","SMDI","2026-04-28",{"date":97,"type":36},"2026-05-05",{"date":99,"type":36},"2026-02-23",{"date":33,"type":20},{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100556323","prediction-of-decompensation-and-hcc-development-in-advanced-chronic-liver-disease-100556323","NCT06523608","Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease","Prediction of Decompensation and HCC Development in Patients With Advanced Chronic Liver Disease by the PLEASE and M10S20 Algorithms","DETECT","Inclusion Criteria:\n\n* The patient admitted\u002Freferred to study center is hospitalized or is an outpatient with advanced chronic liver disease (based on the BAVENO criteria)\n\nExclusion Criteria:\n\n* Pregnancy\n* Age \\\u003C18\n* Evidence of current malignancy except for non-melanocytic skin cancer\n* Presence or history of severe extra-hepatic diseases (e.g., chronic renal failure requiring hemodialysis, severe heart disease (New York Heart Association (NYHA) \\> II); severe chronic pulmonary disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) \\> III), severe neurological and psychiatric disorders).\n* Human Immunodeficiency Virus (HIV) positive patients.\n* Previous liver or other transplantation.\n* Patients who decline to participate or who cannot provide prior written informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.\n* Physician's denial (e.g. the investigator considers that the patient will not follow the protocol scheduled).",{"count":111,"type":20},600,"2 Years","OBSERVATIONAL","The aim of this observational study is to predict the short- and long-term development of acute severe disease events, de novo hepatocarcinoma (HCC) and mortality in patients with advanced chronic liver disease using the M10S20 (Liver stiffness and Model for End-Stage Liver Disease Score \\[MELD\\] combined) and PLEASE (Platelet, Etiology, Age, Sex und Elastography) scores, as well as the validation of the cost-effectiveness of the algorithm.\n\nPatients in this study are randomly divided into two groups:\n\n* Control group: patients are examined according to the current clinical standard protocol (biannual follow-up).\n* Stratified surveillance program:\n\n  * High-risk patients will receive an appointment for a hospital visit every 3 months.\n  * Low-risk patients could receive an appointment in one year. When necessary, if decompensation develops or HCC occurs, patients could be followed-up more frequently.",[116,117,118,119],"Liver Diseases","Hepatocellular Carcinoma","Hepatocarcinoma","Advanced Chronic Liver Disease","2025-12-15",{"date":122,"type":36},"2025-12-22",{"date":124,"type":36},"2024-09-01",{"date":126,"type":20},"2027-09",{"name":42,"class":43},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":44},"100597248","multicenter-trial-on-surgical-outcome-and-quality-of-life-in-juxta-medullary-tumors-100597248","NCT07056023","Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors","EURJMT","Inclusion Criteria:\n\n* Adult, age ≥18 years, patients treated on intraspinal, extra medullary tumor\n* Patients must have sufficient cognitive and language skills to give informed consent\n\nExclusion Criteria:\n\n* Absence of informed consent\n* Lack of ability to consent\n* Primary bone tumors invading the intra-spinal space\n* Vertebral metastasis",{"count":136,"type":20},100,"Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary objectives: Assessment of variables leading to better outcome through regression analysis: 1. Influence of surgical approach on functionality, pain, and quality of life 2. Comparison between patient with severe neurological (McCormick scale 3-5) to patients with mild deficits (McCormick scale 1-2) 3. Role of intraoperative monitoring (IOM) in extent of resection and neurological deficits Assessment of treatment variations: 1. Assessment of risk factors for incomplete resection 2. Non inferiority of unilateral approach to achieve gross total resection of spinal meningioma, schwannoma and cauda ependymoma 3. Role of bed rest after surgery to prevent cerebro-spinal fluid leakage 4. Influence of laminectomy on cerebro-spinal fluid leakage Quality indicators: assessments of length of hospital stay, 30- and 90-days re-admissions, 30- and 90-days re-surgery, nosocomial infections",[139,140],"Intraspinal Tumor","Juxtamedullary Tumor",[142,143,144,145],"intra-dural tumors","spinal meningioma","spinal schwannoma","spinal ependymoma","2025-07-02",{"date":148,"type":36},"2025-07-09",{"date":150,"type":36},"2025-05-01",{"date":152,"type":20},"2027-12",{"name":42,"class":43},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100592879","multiparametric-mri-for-characterization-of-hepatocellular-carcinoma-100592879","NCT06999174","Multiparametric MRI for Characterization of Hepatocellular Carcinoma","Multiparametric MRI for Optimized Imaging-based Characterization and Therapy Management of Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed or suspected diagnosis of HCC\n* Scheduled to receive TACE or SIRT as part of standard clinical care\n* Eligibility for liver MRI\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., pacemakers, ferromagnetic implants, severe claustrophobia)\n* Known allergy or intolerance to gadolinium-based contrast agents\n* Renal insufficiency with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m²\n* Pregnancy or breastfeeding\n* Inability to provide informed consent",{"count":162,"type":20},128,"This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC). The goal is to evaluate whether advanced MRI parameters can support noninvasive diagnostic assessments and personalized treatment plans for patients with HCC. The study is being conducted at a single university center in Germany and includes adult patients with confirmed or suspected HCC. Participants will undergo standardized multiparametric MRI examinations, and the imaging data will be correlated with clinical, pathological, and therapeutic outcomes. No study-specific interventions or medications will be administered.",[165],"Hepatocellular Carcinoma (HCC)",[167,168,169],"Multiparametric MRI","TACE","SIRT","2025-06-28",{"date":146,"type":36},{"date":150,"type":36},{"date":174,"type":20},"2028-05-01",{"name":42,"class":43},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100565942","improving-pharmacological-transition-of-palliative-care-patients-from-inpatient-to-outpatient-care-100565942","NCT06648733","Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care","Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care (Optimierung Der Pharmakologischen Überleitung Von Palliativpatient:Innen Von stationär Nach Ambulant)","EntMedPall","Inclusion Criteria:\n\nAll individual indications for general and specialised palliative care as part of routine clinical practice (e.g.):\n\n* advanced, malignant tumour disease\n* advanced, chronic obstructive pulmonary disease\n* Patients with advanced disease and limited life expectancy (approx. 12 months) Further care in the SOPC Muenster (prospective data) Sufficient understanding of the German language to be able to understand the information and consent form\n\nExclusion Criteria:\n\nImpossibility of understanding the information and declaration of consent.",{"count":185,"type":20},200,[23],"The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.",[189,190,191],"Cancer","Heart Failure","COPD",[193],"Palliative Care","2025-06-10",{"date":196,"type":36},"2025-06-13",{"date":198,"type":36},"2024-06-20",{"date":200,"type":20},"2025-12-31",{"name":42,"class":43},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100591462","video-tumorboard-plus-100591462","NCT06980740","Video-Tumorboard PLUS","vTB+","Inclusion Criteria:\n\n* The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .\n\nInclusion criteria for patients:\n\n* Minimum age 18 years\n* Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease\u002Fdiagnosis, especially in the case of:\n\n  * Malignant melanoma from stage IIB\n  * Malignant melanoma and stage shift\u002Frecurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension\u002F infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.\n\nIn this case, revenue\u002Fcost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.\n\nInclusion criteria for external doctors:\n\n* has a medical license\n* has dermatological patients who are eligible to be presented in the vTB+\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet the following criteria:\n\n* Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.\n* No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.",{"count":210,"type":20},300,"In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.",[213,214],"Malignant Melanoma","Telemedicine",[213,214],"2025-05-16",{"date":218,"type":36},"2025-05-20",{"date":150,"type":36},{"date":221,"type":20},"2027-05-31",{"name":42,"class":43},3,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},"100578339","eye-diseases-treated-with-interoperable-medical-informatics-100578339","NCT06810011","Eye Diseases \"Treated\" With Interoperable Medical Informatics","EyeMatics - Eye Diseases \"Treated\" With Interoperable Medical Informatics","EyeMatics","Inclusion Criteria:\n\n* OPS code: \"5-156.9 Injection of drugs into the posterior segment of the eye\"",{"count":233,"type":20},2000,"The overarching goal of EyeMatics is to promote an interoperable, sustainable infrastructure for the integration and sharing of data from clinical research to improve personalized medicine in ophthalmology. To achieve this, EyeMatics bundles the expertise and preliminary work of the four consortia of the Medical Informatics Initiative (MII) and the ophthalmological centers of excellence in Germany. The perspective and concerns of patients will be strongly incorporated into the project work through close cooperation with patient representatives and the inclusion of patient feedback on quality of life and treatment success.\n\nEyeMatics aims to improve the understanding of the therapeutic success of eye diseases that are usually treated with intravitreal surgical medication (IVOM). To this end, an exemplary analysis platform for \"real\" clinical data will be provided and a dashboard for data visualization and analysis will be developed as a web application. The dashboard is to be introduced at all participating hospital sites for research purposes.",[236],"Intravitreal Injections",[238,239,240,241,242],"Artificial intelligence","Core dataset","Intraviteal Injection","Medical Informatics","Data exchange","2025-01-30",{"date":245,"type":36},"2025-02-05",{"date":247,"type":36},"2024-03-01",{"date":249,"type":20},"2028-02-29",{"name":42,"class":43},6,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100473845","filter-lifespan-in-continuous-renal-replacement-therapy-100473845","NCT05450185","Filter Lifespan in Continuous Renal Replacement Therapy","The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial","CRRTInfO","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Critically ill patients with dialysis-dependent AKI\n* Continuous renal replacement therapy (CRRT)\n* Written informed consent\n\nExclusion Criteria:\n\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.73m2\n* Chronic dialysis dependency\n* Kidney transplant\n* (Glomerulo-)nephritis, interstitial nephritis, vasculitis\n* Patients on immunosuppression\n* Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)\n* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator",{"count":111,"type":20},"The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.",[263,264,265],"Critically Ill","Continuous Renal Replacement Therapy","Infections","2024-12-06",{"date":268,"type":36},"2024-12-12",{"date":270,"type":36},"2023-03-02",{"date":272,"type":20},"2025-08",{"name":42,"class":43},5,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":44},"100369955","isrt-20-gy-for-indolent-localized-gastrointestinal-gi-lymphoma-100369955","NCT04097067","ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma","Phase II Trial to Assess the Efficacy of Low Radiation Dose of 20 Gy for the Treatment of Marginal Zone Lymphoma or Follicular Lymphoma Stage I-II Localized in the Stomach or the Duodenum","Inclusion Criteria:\n\n* primary indolent gastric or duodenal lymphoma\n* pathology: marginal zone lymphoma (MZL) or follicular lymphoma (FL)\n* stage: clinical stage I or II (Ann Arbor classification)\n* H. pylori negative or antibiotic resistant lymphoma\n* IPI or FLIPI score low - high (0-4)\n* any size of tumor or affected lymph nodes\n* male or female with age ≥ 18 years\n* performance status ECOG 0 - 3\n* written informed consent by the patient\n\nExclusion Criteria:\n\n* prior radiation treatment of the gastrointestinal lymphoma\n* stage: clinical stage III or IV (Ann Arbor classification)-unability to understand the informed consent or unwillingness to participate in the study\n* severe comorbidity or organ dysfunction contraindicating the use of RT (liver cirrhosis Child-Pugh C, chronic obstructive pulmonary disease GOLD 4, heart insufficiency NYHA IV, dialysis dependent renal insufficiency, uncontrolled epilepsy)\n* known seropositivity for HIV\n* acute hepatitis B or C infection\n* chronic inflammatory bowel disease\n* prior malignant disease (exclusion: basalioma, non-metastasized solid tumor in constant remission diagnosed \\>3 years ago)\n* pregnancy or breastfeeding\n* active substance abuse or severely compromised compliance",{"count":283,"type":20},83,[23],"This trial studies the effectivity of low-dose radiation therapy with 10x2Gy for the treatment of patients with stage I-II stomach or duodenal Lymphoma (Marginal Zone or Follicular)",[287,288],"Follicular Lymphoma (Gastric or Duodenal)","Marginal Zone Lymphoma (Gastric or Duodenal)",[290,291,292,293,294,295,296,297,298,299,300],"Lymphoma","Lymphoma, B-Cell, Marginal Zone","Neoplasms by Histologic Type","Neoplasms","Lymphoproliferative Disorders","Lymphatic Diseases","Immunoproliferative Disorders","Immune System Diseases","Lymphoma, B-Cell","Lymphoma, Non-Hodgkin","Lymphoma, follicular","2024-08-26",{"date":303,"type":36},"2024-08-27",{"date":305,"type":36},"2019-09-01",{"date":307,"type":20},"2025-08-31",{"name":42,"class":43},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":44},"100460407","effect-of-an-intervention-to-prevent-acute-kidney-injury-versus-standard-care-in-high-risk-patients-after-major-surgery-100460407","NCT05275218","Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery","Effect of an Extended \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Bundle Versus Standard of Care Therapy on Persistent Acute Kidney Injury in High-risk Patients After Major Surgery","PrevProgAKI","Inclusion Criteria:\n\n1. Adult patients (age ≥18 years)\n2. Moderate or severe AKI ((defined by the 2012 KDIGO criteria, KDIGO stage 2 and 3), determined by either serum creatinine or urine output) within 72h after a surgical procedure\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Dialysis-dependent chronic kidney disease\n2. Prior kidney transplant\n3. Infections with human immunodeficiency virus or hepatitis\n4. Hepatorenal syndrome\n5. Pregnancy or breast-feeding\n6. Participation in another interventional trial that investigates a drug that affects the kidney function within the last 3 months\n7. Persons held in an institution by legal or official order\n8. Persons with any kind of dependency on the investigator or employed by the responsible institution or investigator",{"count":318,"type":20},480,[23],"There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury.\n\nTo investigate whether an implementation of a supportive extended care \"bundle\" in high-risk patients for persistent acute kidney injury (AKI) can reduce the occurrence of persistent surgical AKI.\n\nIn order to investigate whether the extended KDIGO bundle can prevent persistent AKI in patients with high chemokine ligand 14 (CCL14) as well as in patients with low CCL14, patients will be randomized with stratification by the CCL-value.",[322],"Acute Kidney Injury (Nontraumatic)",[324,325,326],"surgery","biomarker","CCL14 protein","2024-07-30",{"date":329,"type":36},"2024-08-01",{"date":331,"type":36},"2023-03-22",{"date":333,"type":20},"2025-12",{"name":42,"class":43},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":44},"100544858","semibranch-registry---retrospective-100544858","NCT06374355","Semibranch Registry - Retrospective","Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Retrospective, Multicentre Registry","* Patient has been treated with the semibranch stentgraft\n* Patient is over 18 years old",{"count":136,"type":20},"The goal of this registry is to evaluate the semibranch in branched endovascular arotic repair, which is a new tool in endovascular branched aortic repair.",[345,346,347],"Aortic Aneurysm","Endovascular Aortic Repair","Stent-Graft Endoleak","2024-07-02",{"date":350,"type":36},"2024-07-03",{"date":348,"type":36},{"date":353,"type":20},"2030-10",{"name":42,"class":43},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":361,"targetDuration":362,"studyType":113,"phases":4,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":44},"100520629","outcome-of-the-semibranch-in-pararenal-and-thoracoabdominal-aortic-pathologies-a-prospective-multicentre-registry-100520629","NCT06059053","Outcome of the Semibranch in Pararenal and Thoracoabdominal Aortic Pathologies. A Prospective, Multicentre Registry.","Inclusion Criteria:\n\n* 18 years or older\n* Presence of pararenal or thoracoabdominal aortic pathology\n* Treatment planned a semibranch device branch from Artivion\n* Availability of the patients during the follow up period\n* Informing patients about the study and providing written informed consent\n\nExclusion Criteria:\n\n* Women of childbearing age\n* Patients under 18 years",{"count":136,"type":20},"1 Year","The goal of this registry is to evaluate the semibranch in branched endovascular aortic repair, which is a new tool in endovascular branched aortic repair.",[345,346,347],"2024-03-25",{"date":367,"type":36},"2024-03-26",{"date":369,"type":36},"2024-01-12",{"date":371,"type":20},"2027-03-31",{"name":42,"class":43},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":362,"studyType":113,"phases":4,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":401,"locationsCount":44},"100480001","outcome-of-a-triple-inner-branched-aortic-arch-stentgraft-a-prospective-multicenter-registry-100480001","NCT05530304","Outcome of a Triple Inner Branched Aortic Arch Stentgraft. A Prospective, Multicenter Registry.","triple_branch","Inclusion Criteria:\n\n* 18 years or older\n* Presence of Aortic arch pathology\n* Treatment planned with triple inner branch from Terumo Aortic\n* Availability of the patients during the follow up period\n* Informing patients about the study and providing written informed consent\n\nExclusion Criteria:\n\n* Women of childbearing age\n* Patients under 18 years",{"count":19,"type":20},"Outcome of a triple inner branched aortic arch stentgraft. A prospective, mulitcenter registry.",[383,384,385,386],"Aortic Arch","Aortic Arch Aneurysm","Dissection of Aortic Arch","Triple Branch",[388,389,390,391,392,393,394],"Aortic arch pathologies","Aortic arch aneruysm","Aortic arch dissection","triple branch","stentgraft","Double branch","Inner branch","2023-09-11",{"date":397,"type":36},"2023-09-13",{"date":399,"type":36},"2023-02-09",{"date":371,"type":20},{"name":42,"class":43},{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":410,"targetDuration":411,"studyType":113,"phases":4,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":424},"100241294","international-primary-ciliary-dyskinesia-pcd-registry-100241294","NCT02419365","International Primary Ciliary Dyskinesia (PCD) Registry","International Prospective Primary Ciliary Dyskinesia (PCD) Registry for Systematic Data Collection on Incidence, Clinical Presentation, Treatment and Course of the Disease","PCDregistry","Inclusion Criteria\n\nPatients of any age who fulfil the diagnostic criteria below are eligible:\n\nClinical presentation consistent with PCD and consistent findings specific for PCD in at least two of the following methods:\n\nhigh frequency video microscopic finding transmission electron microscopy finding immunofluorescence finding low nasal NO concentration\u002Fproduction demonstration of biallelic disease-causing mutations by genotyping\n\nGiven the complexity of diagnosing PCD, it is anticipated that not all patients will meet these definite diagnostic criteria. Therefore, individuals with typical clinical symptoms and only one abnormal diagnostic test are also eligible to enter the registry. These cases usually are considered to have a possible PCD diagnosis with exceptions made on an individual basis.\n\nExclusion Criteria Failure or unwillingness to give written informed consent. Missing qualification to perform legal acts or insufficient cognitive ability to give informed consent. A second disease is no exclusion criteria for including data in the PCD-Registry, especially since it is one of the fundamental goals, to learn about co-morbidities.",{"count":233,"type":20},"20 Years","The purpose of the international prospective PCD Patient Registry is to systematically measure, survey and compare different aspects of PCD manifestation, course and treatment, to provide data for epidemiological research and to identify special patient groups suitable for multi-center trials.\n\nThis International PCD Registry is also part of the European Reference Network ERN-LUNG. We follow the recommendations of the EU Expert Committee on Rare Diseases (EUCERD), which recommend an international interoperability of registries and databases to pool and exchange knowledge and data on rare diseases.",[414],"Primary Ciliary Dyskinesia (PCD)",[414],"2022-11-25",{"date":418,"type":36},"2022-11-28",{"date":420,"type":4},"2014-01",{"date":422,"type":20},"2030-12",{"name":42,"class":43},2,""]